A WORD FROM PHARMASCIENCE INC.’S CHIEF OPERATING OFFICER ABOUT THE CORONAVIRUS (COVID-19)

Montreal, March 6, 2020 – As one of the largest manufacturers of generic pharmaceuticals in Canada and the largest in Québec, Pharmascience continues to monitor the global impact of the COVID-19 virus. We wish to reassure patients and health care professionals who utilize Pharmascience or Pendopharm products that we do not foresee at this point in time any interruption in our ability to supply high quality pharmaceutical products.

We are closely monitoring the situation and will continue to work with our suppliers in order to mitigate any inventory shortages, and with our employees to avoid their potential exposure to the virus. Pharmascience is minimizing business travel to and from COVID-19 hot zones in accordance with Health Canada and WHO travel advisories. We are closely monitoring the situation and will do our utmost to ensure our employees are not put in harm’s way.

Should the situation change in the weeks and months ahead, we are committed to updating our clients and the general public on any new information as it becomes available.

Thank you,

 

Jean-Guy Goulet
Chief Operating Officer
Pharmascience Inc.

Published in

COVID